Therapeutic Antibodies

#Biologics #Life sciences #Pharmaceuticals

Podcast: The changing drug discovery landscape

This is the latest episode of the free DDW podcast, “What does the changing drug discovery and development landscape mean for the future?”. It covers three articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “The… Read More

#News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Interview #Oncology #PharmEnable

Sitting down with… PharmEnable

Listen to this article on the DDW podcast: Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. RA: How is Pharmenable aiming to replicate the specificity of biologics… Read More

#Exclusive Content

mRNA vaccines
#Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #mRNA #Vaccines

Preparing for new-era drug modalities with technology 

Listen to this article on the DDW podcast: Samsung Biologics’ Senior Vice President, James Park, explores the opportunities emerging for CDMOs to support mRNA developers as they explore new therapeutic areas for patients.  Prior to the pandemic, messenger RNA (mRNA) drug development was niche and predominantly pointed at different disease targets,… Read More

#Exclusive Content

Cat in a box
#Allergen immunotherapy #Allergy #Monoclonal antibodies

Combination treatment could be more effective for cat allergy

New research has shown that standard cat allergy treatment can be enhanced to make it more effective and faster acting, and the benefits last for a year after treatment ends. These results show for the first time that adding a cytokine inhibitor to allergy shots could reduce allergic rhinitis symptoms… Read More

#News #Trending News

eBook cover
#Antibody-based therapeutics #Drug development #Monoclonal antibodies

Efficiently develop antibody-based therapeutics

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing.  Antibodies are affected by many factors along their journey to become therapeutics. Read More

#Resources

Antibodies
#Antibody #Antibody-based therapeutics #eBook #Monoclonal antibodies #Stability characterisation

New eBook: Efficiently develop antibody-based therapeutics 

In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing.  Antibodies are affected by many factors along their journey to become therapeutics. Read More

#News

#Biologics #Bioproduction #Bioseparation #Cell and gene therapy #Purification technology

How to achieve greener, faster and more cost-effective bioprocessing workflows 

Astrea Bioseparations has launched its Nereus LentiHERO lentiviral vector (LVV) purification technology commercially. Incorporating AstreAdept, the company’s proprietary nanofiber material, this solution has been created to address the challenges associated with purifying the large and fragile products used in cell and gene therapy. AstreAdept is a proprietary bioseparations material that… Read More

#News

Crohn's disease
#Biologics #Crohn's disease #Exclusive Enteral Nutrition #Gut microbiome #Nutrition

Potential new treatment for Crohn’s disease patients in Scotland

A new clinical trial, led by the University of Glasgow and NHS Greater Glasgow and Clyde (NHSGGC), hopes to improve treatment options for patients with Crohn’s disease.   The BIOPIC (BIOlogics and Partial enteral nutrition In adults with active ileocolonic Crohn’s disease) study, which is in collaboration with hospitals… Read More

#News

Antibodies
#Afucosylated mAb expression #Antibody #Antibody-dependent cellular cytotoxicity #Glycoengineered antibodies #Monoclonal antibodies

New App Note: Afucosylated mAb expression and antibody efficacy

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. The absence of fucose on the Fc N-glycan increases IgG1 Fc binding affinity to the FcγRIIIa on immune effector cells like natural killer cells. It results in… Read More

#News

#Biologics #Cell and gene therapy #Malaria #Manufacturing #Oncology

This week in drug discovery (26-30 September)

This week in drug discovery (26-30 September) News round-up by DDW Editor Reece Armstrong. An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of  identifying cancer cells and a manufacturing system could… Read More

#News

Asthma inhaler
#Asthma #Biologics

First and only biologic approved in the EU in patients with severe asthma 

AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.  The approval by the European Commission was based on results… Read More

#News

Antibody
#Drug discovery #Monoclonal antibodies #Webinar

Webinar: Octet BLI for antibody discovery

Join DDW & Charles River Laboratories in this free webinar examining how the company uses Octet Bio-Layer Interferometry (BLI) to help inform its drug discovery campaigns and workflows. In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into… Read More

#News

Child with eczema
#Atopic dermatitis #Biologics #Dermatology #Eczema #Monoclonal antibodies

First biologic therapy for young children with severe eczema

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal… Read More

#News

Vials for medical research
#Antibodies #Biomedical research #Drug development #Drug discovery #In vitro

New anti-evolocumab antibodies could aid drug development

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels.  These sequence-defined, recombinant antibodies are… Read More

#News

SARS-CoV-2 virus particles
#Antibodies #Biomarkers #Clinical trials #Coronavirus #Covid-19 #Drug development #SARS-CoV-2

SARS-CoV-2 antigen levels could predict patient outcomes

The amount of SARS-CoV-2 antibodies in the blood of patients hospitalised with Covid-19 could be used to predict illness severity and other clinical outcomes.  A new study, published in the Annals of Internal Medicine, shows that higher levels of viral antigen in the blood, which… Read More

#Covid-19 #News

#Antibody #Drug discovery #Monoclonal antibodies #Webinar

Webinar – applications in early monoclonal antibody discovery

In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. The webinar elaborates on the use of the Octet BLI for quality control of proteins,… Read More

#News